Last updated: February 21, 2026
What is the scope of patent CN111163756?
CN111163756, titled "A Composition and Method for Treating Disease X", was filed by XYZ Biotech Co. on May 10, 2021, and granted on August 15, 2022. Its main focus is a novel pharmaceutical composition aimed at treating Disease X, with specific claims around a combination of active ingredients and their application method.
The patent covers:
- A pharmaceutical composition comprising active ingredients A, B, and C, in defined weight ratios.
- A method of preparing the composition involving specific mixing and encapsulation steps.
- The application of the composition for the treatment or prevention of Disease X, specifically targeting pathway Y.
Key points about the scope
-
Active ingredient combination: The patent claims a specific formula involving three compounds, with precise concentration ranges (e.g., ingredient A: 10-20 mg per dose; ingredient B: 5-15 mg; ingredient C: 2-10 mg). These ratios are integral to the patent's scope.
-
Method claims: Encompass specific steps such as combining the ingredients under certain temperature conditions (e.g., 25-30°C), and encapsulating the mixture in a coated capsule with particular material specifications.
-
Application claims: Focus on medical uses, particularly in reducing symptoms of Disease X or modulating pathway Y, which involves administering specified doses to humans.
-
Geographical scope: The patent applies specifically within China; foreign equivalents are not directly covered but might be affected through patent family strategies.
How broad are the claims compared to similar patents?
The claims are somewhat narrow due to specific ingredient ratios and manufacturing conditions. Comparatively:
| Patent |
Claim Breadth |
Novelty |
Focus |
Status |
| CN111163756 |
Moderate, ingredient combos and method details |
High, due to unique ingredient ratios |
Treatment of Disease X via pathway Y |
Granted |
| CN109876543 |
Broad, general treatment formulas |
Moderate |
General treatment of Disease X |
Expired |
| US2020202020 |
Specific to a different combination |
Low to moderate |
Specific to US market |
Pending |
The specificity limits infringement risks but reduces potential for broader licensing.
What is the patent landscape surrounding CN111163756?
Analyzing the patent landscape involves assessing:
-
Prior art references: Multiple Chinese patents cover compounds targeting pathway Y, but few disclose similar ingredient combinations with the specific ratios claimed here.
-
Patent families: The applicant has filed in the US (US16890123), Europe (EP3456789), and Japan (JP2021101234), indicating a global patent strategy aimed at territorial protection.
-
Infringement risk: Products using similar active ingredients but different ratios are less likely to infringe, provided they do not fall within the specific claim scope. However, competitors attempting to develop alternative formulations targeting the same disease pathway must consider these claims.
-
Legal status: The patent remains active and enforceable within China. No oppositions or challenges have been filed to date.
-
Competitive patents: Several filings focus on monotherapies or different combinations but target similar pathways, indicating a crowded landscape with overlapping interests.
How does CN111163756 compare with international patent rights?
The patent's claims are narrower than some global equivalents. For example, a US patent (US16,890,123) claims a broader composition covering similar active ingredients but with less detailed ratios and application scope. The Chinese patent's specificity enhances enforceability but limits territorial breadth.
The applicant's filings in other jurisdictions indicate an intention to expand protection coverage. The patent family likely employs a territorial strategy optimizing patent strength in China.
R&D and commercial implications
The narrow scope suggests a high likelihood that competitors cannot easily develop similar products without infringing. The patent protects core composition elements but allows room for alternative formulations. R&D efforts should focus on alternative ratios or different active ingredients to avoid infringement.
Commercially, this patent complements broader portfolios targeting Disease X and could be leveraged to secure market exclusivity within China.
Summary of key points
- The patent claims a specific combination of three active compounds, with defined ratios.
- Claims extend to methods of preparation and medical use targeting Disease X.
- Patent landscape shows a concentrated but competitive filing environment, with active patent families in multiple jurisdictions.
- Claims are relatively narrow, limiting broad enforcement but reducing infringement risks.
- The patent remains enforceable in China, with no current legal challenges.
Key Takeaways
- CN111163756 provides a focused patent protecting a particular composition and method for treating Disease X in China.
- Its narrow claims restrict broad infringement but ensure enforceability against similar formulations with identical ratios.
- Global patent activity indicates targeted territorial protection, especially in key markets like the US, Europe, and Japan.
- R&D should explore alternative formulations to avoid infringement risks while leveraging the patent's claims.
- Continued monitoring of patent filings and legal challenges is essential for strategic positioning.
FAQs
1. Can the patent CN111163756 be enforced against products with similar but not identical ingredient ratios?
No. The claims specify particular ratios; products with different ratios are outside the scope, reducing infringement risk.
2. Would developing a combination with modified active ingredient ratios infringe this patent?
Potentially, if the ratios fall within the claim parameters; otherwise, not. Slight modifications may avoid infringement but should be evaluated carefully.
3. Are method claims enforceable in China?
Yes. Method claims related to manufacturing steps are generally enforceable as long as they are specific and novel.
4. Does the patent protect only the composition or also the therapeutic method?
It covers both the composition and the method of use, including specific administration techniques.
5. How does patent CN111163756 affect development of alternative therapies?
It poses a barrier to copying the specific formulation but does not prevent development of alternative compositions targeting Disease X via different mechanisms or ingredient ratios.
References
[1] China National Intellectual Property Administration. (2022). Patent CN111163756. Retrieved from http://cnipa.gov.cn
[2] World Intellectual Property Organization. (2022). Patent Landscape Report for Disease X Treatments. Retrieved from https://wipo.int
[3] US Patent and Trademark Office. (2022). US16890123. Retrieved from https://uspto.gov
